Peter Humaidan
16
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
13%
2 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality
Role: lead
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Role: lead
The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota
Role: lead
The Correlation Between Luteal Serum Progesterone and Live Birth Rate
Role: lead
Characterizing Follicles From Auto-transplanted Ovarian Tissue
Role: lead
Single and Double DNA Strand Breaks in Males With Unexplained Infertility Attending Fertility Treatment
Role: lead
Can Virtual Reality Technology Improve the Patient Experience in Oocyte Retrieval?
Role: lead
The Microbiome of Infertile Couples and Its Effect on Their Reproductive Outcomes
Role: lead
The Effect of a Multimodal Lifestyle Program on Male Fertility
Role: lead
Is Oxidative Stress in Semen Reduced by Lifestyle Intervention
Role: lead
The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in Oocyte Donors
Role: lead
The Temporo-spatial Dynamics of Genital Tract Microbiota
Role: lead
The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients
Role: lead
Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation
Role: lead
Daytime Profile of Salivary Progesterone
Role: lead
Therapeutic Lactose to Support Vaginal Microbiota
Role: lead
All 16 trials loaded